Industry

Aridhia's Data Platform Used in Major European Research Collaboration to Tackle Alzheimer's Dementia

AridhiaAridhia has announced that it is among 36 organisations behind a ground-breaking Innovative Medicines Initiative research programme that aims to build a platform for efficient testing of innovative treatments for the prevention of Alzheimer's dementia.

Aridhia's data and analytics platform, AnalytiXagility, has been selected for use in the European Prevention of Alzheimer's Dementia (EPAD) project, a powerful research collaboration between European organisations in the public and private sectors which, unlike previous projects, focuses on prevention of dementia in the early stages of the disease.

The project will collaborate with existing cohorts to create a register, identifying 24,000 people across Europe who may be at risk of developing the disease later in life. 6,000 of these people will be invited to join EPAD's cohort of 'at risk' subjects to undergo standardised tests and follow-ups. Of these, approximately 1,500 people will be selected to take part in EPAD's proof of concept adaptive trials of innovative drugs.

Rodrigo Barnes, Chief Technology Officer at Aridhia, said that AnalytiXagility has been chosen because it offers a strong collaborative platform that is accessible to all of the consortium partners and is able to carry out advanced data analytics that can interrogate any kind of data.

"AnalytiXagility offers EPAD a flexible working environment that is collaborative, neutral and has the ability to carry out advanced data analytics during complex trials.

"It will be used as part of a trial engine for the EPAD cohort of 6,000 subjects and the further 1,500 participants who will be asked to take part in the project’s proof of concept adaptive trials of drug candidates or drug combinations that have been specially designed to prevent Alzheimer's dementia.

"With no cure for Alzheimer's and little in the way of treatment, it is vital that we understand and learn how to prevent Alzheimer’s dementia when in its early phases."

The University of Edinburgh is working with Aridhia to trial the EPAD cohort. Professor Craig Ritchie, one of the project’s co-ordinators who is based at the University said: "EPAD is a game-changing project. There is commitment from a wide range of organisations across academia, pharma and public health, to get to the root causes of dementia, to understand how the disease develops over the decades before symptoms become visible, and treat patients at an early stage."

"The EPAD model gives us the opportunity to work together to understand who is more likely the get the disease and how they can be treated early, and effectively."

EPAD promises to deliver a more efficient research model which can streamline the recruitment of patients and enable likely drug candidates to be accelerated straight into Phase III trials, the last stage before a new drug is licenced for use.

Furthermore, all data collected from the cohort will be made public to allow researchers the chance to improve their understanding of the disease, especially in pre-symptomatic phases.

Aridhia's involvement in EPAD cements its commitment to globally significant collaborative research projects, and to addressing one of society’s most challenging diseases. Earlier this year the company announced that AnalytiXagility has been chosen to underpin the three year Moneta Research project, supporting their research into identifying people most likely to develop Alzheimer's dementia.

About Aridhia Informatics
Founded in 2007, Aridhia is a world-leading clinical and translational informatics company developing technology and capability that accelerates the translation of precision medicine and biomedical research into clinical practice. Operating internationally on projects in England, Scotland, Australia, and across Europe, Aridhia works closely with governments, health organisations, research collaborations and academic institutions to transform how care is delivered.

Based in Edinburgh and Glasgow, Aridhia has a 60-strong multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and healthcare experts.

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Most Popular Now

Smartphones and Wearable Devices co…

RADAR-CNS (Remote assessment of disease and relapse - Central Nervous System), a major new research programme supported by the Innovative Medicines Initiative (IMI) start...

Read more

Patientrack Recognised as One of 'T…

UK healthcare technology company Patientrack has been recognised as providing one of the best eHealth solutions anywhere in Europe, in an EU competition focussed on healt...

Read more

Merck in Agreement with HAPPYneuron…

Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in ...

Read more

Mobile Technology: Is the NHS Closi…

Opinion Article by Steve Carvell, head of healthcare at CommonTime. Technology skills are in higher demand than ever. Look across any vertical and developers who can cre...

Read more

Future Health Index 2016

Royal Philips (NYSE: PHG, AEX: PHIA) today launched the results of the first edition of its Future Health Index (FHI), an extensive international study which explores how...

Read more

Philips and SURFsara Team up to Pro…

Royal Philips (NYSE: PHG; AEX: PHIA) and SURFsara (a subsidiary of the SURF cooperation), the leading Dutch high-performance supercomputing and data infrastructure provid...

Read more

New Digital Centre to Help Improve …

A new centre for digital innovation which could transform the way mental health care is provided will be launched today. The Centre for Translational Informatics (CTI) is...

Read more

Innovations in Neuroimaging Lead to…

The current special issue of Technology and Innovation, Journal of the National Academy of Inventors, Volume 18, Number 1 (all open access), is devoted to the evolution o...

Read more

Tech Tour Healthtech Summit 2016

21 - 22 June 2016, Lausanne, Switzerland. The 2016 Healthtech Summit is the leading independent European event for investment in Digital Health and Medtech. The summit a...

Read more

eHealth Innovation Days Conference

8 - 9 September 2016, Flensburg, Germany. The first eHealth Innovation Days Conference at Flensburg University of Applied Sciences will offer a platform for networking, ...

Read more

Smart Sensors and Innovation Are th…

Royal Philips (NYSE: PHG; AEX: PHIA) has announced the Philips Sonicare FlexCare Platinum Connected, its latest innovation that uses Smart Sensor technology to help consu...

Read more

2016 Biomax Symposium: Bringing Big…

24 June 2016, Martinsried, Germany. Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsr...

Read more

Digest Newsletter

Subscribe to our weekly Newsletter and stay updated on the latest eHealth News. Subscribe now, it's free!
© eHealthNews.eu 2006 - 2016